STAT (8/15, Begley) reports that despite an analysis that found there are “literally zero” experimental Alzheimer’s medications being tested in late stage trials to treat moderate to severe cases, thus far, “no patient advocacy groups uttered a peep in protest.” STAT explains, “For more than 20 years drug makers and academic scientists pursued treatments to slow or reverse dementia by targeting amyloid plaques in the brain,” but “every last one failed.” Companies are now focusing on preventing the disease in younger people or trying to address behavioral symptoms such as agitation.
Related Links:
— “As Alzheimer’s drug developers give up on today’s patients, where is the outrage?, “Sharon Begley, STAT, August 15, 2018.